201 related articles for article (PubMed ID: 11502520)
21. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
Chen RY; Edwards R; Shaw T; Colledge D; Delaney WE; Isom H; Bowden S; Desmond P; Locarnini SA
Hepatology; 2003 Jan; 37(1):27-35. PubMed ID: 12500185
[TBL] [Abstract][Full Text] [Related]
22. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
23. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil.
Balakrishna Pai S; Liu SH; Zhu YL; Chu CK; Cheng YC
Antimicrob Agents Chemother; 1996 Feb; 40(2):380-6. PubMed ID: 8834884
[TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.
Kwon SY; Park YK; Ahn SH; Cho ES; Choe WH; Lee CH; Kim BK; Ko SY; Choi HS; Park ES; Shin GC; Kim KH
J Virol; 2010 May; 84(9):4494-503. PubMed ID: 20164224
[TBL] [Abstract][Full Text] [Related]
26. rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B.
Liu LJ; Wang JH; Du SC; Tian JH; Yang RF; Wei L
J Viral Hepat; 2010 Mar; 17 Suppl 1():66-72. PubMed ID: 20586936
[TBL] [Abstract][Full Text] [Related]
27. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
Xiong X; Flores C; Yang H; Toole JJ; Gibbs CS
Hepatology; 1998 Dec; 28(6):1669-73. PubMed ID: 9828233
[TBL] [Abstract][Full Text] [Related]
28. Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.
Zhang Y; Zhang Y; Kang Y; Wang J; Liu H; Zhu H; Qin Y; Mao R; Lin X; Lu M; Zhang J
J Virol Methods; 2014 Jun; 201():51-6. PubMed ID: 24583110
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
[TBL] [Abstract][Full Text] [Related]
30. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Walters KA; Tipples GA; Allen MI; Condreay LD; Addison WR; Tyrrell L
Antimicrob Agents Chemother; 2003 Jun; 47(6):1936-42. PubMed ID: 12760870
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.
Rodriguez C; Chevaliez S; Bensadoun P; Pawlotsky JM
Hepatology; 2013 Sep; 58(3):890-901. PubMed ID: 23505208
[TBL] [Abstract][Full Text] [Related]
32. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
33. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
Yang H; Westland CE; Delaney WE; Heathcote EJ; Ho V; Fry J; Brosgart C; Gibbs CS; Miller MD; Xiong S
Hepatology; 2002 Aug; 36(2):464-73. PubMed ID: 12143057
[TBL] [Abstract][Full Text] [Related]
34. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
36. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
37. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reaction-ligase detection reaction.
Wang YZ; Xiao JH; Liu LG; Ye CY; Shen HY; Xu TM; Zhu KZ
Braz J Infect Dis; 2011; 15(6):560-6. PubMed ID: 22218515
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
40. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.
Colledge D; Civitico G; Locarnini S; Shaw T
Antimicrob Agents Chemother; 2000 Mar; 44(3):551-60. PubMed ID: 10681317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]